XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma

NCT04674137 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Bronchial Asthma
Eosinophilic Asthma

Interventions

DRUG: XC8 100 mg
DRUG: Placebo

Sponsor

Chemlmmune Therapeutics LLC

Collaborators

[object Object]